These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 8374548)

  • 1. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron removal in ex-thalassemics after BMT: preliminary results from the phlebotomy program. Italian Cooperative Group for Phlebotomy in Ex-thalassemic.
    Angelucci E; Baronciani D; Giardini C; Argiolu F; Becchelli G; Borgna Pignatti C; Campisi S; Careddu F; Conter V; De Nunzio A
    Bone Marrow Transplant; 1993; 12 Suppl 1():105. PubMed ID: 8374546
    [No Abstract]   [Full Text] [Related]  

  • 3. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus infection and liver disease in children with thalassemia.
    Locasciulli A; Monguzzi W; Tornotti G; Bianco P; Masera G
    Bone Marrow Transplant; 1993; 12 Suppl 1():18-20. PubMed ID: 7690633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of patients with Cooley's anemia: transfusions and splenectomy.
    Piomelli S
    Semin Hematol; 1995 Oct; 32(4):262-8. PubMed ID: 8560283
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcome of thalassemia treated with conventional therapy.
    Borgna-Pignatti C; Zurlo MG; DeStefano P; Boffa C; DeSanctis V; DiPalma A; DiGregorio L; Melevendi C; Piga A; Sabato V
    Bone Marrow Transplant; 1993; 12 Suppl 1():2-4. PubMed ID: 8374554
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 12. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic study in ex-thalassemic patients with iron overload, preliminary observations during phlebotomy therapy.
    Mariotti E; Agostini A; Angelucci E; Lucarelli G; Sgarbi E
    Bone Marrow Transplant; 1993; 12 Suppl 1():106-7. PubMed ID: 8374547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
    Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 19. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of Cooley's anemia.
    Nathan DG
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.